A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers

Summary Background YH4808, a K+‐competitive acid blocker, is under clinical development for the treatment of acid‐related disorders, such as gastroesophageal reflux disease. Aims To determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH4808, compared to placebo an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2017-08, Vol.46 (3), p.337-346
Hauptverfasser:	Yi, S., Lee, H., Jang, S. B., Byun, H. M., Yoon, S. H., Cho, J.‐Y., Jang, I.‐J., Yu, K.‐S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Acidity Acids Adult Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - pharmacology Clinical trials Cross-Over Studies Double-Blind Method Esomeprazole - administration & dosage Esomeprazole - analogs & derivatives Esomeprazole - pharmacokinetics Esomeprazole - pharmacology Gastric Acid - secretion Gastroesophageal reflux Humans Hydrogen ions Hydrogen-Ion Concentration Male Omeprazole pH effects Pharmacodynamics Pharmacokinetics Potassium Randomization Secretion Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!